Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Identifieur interne : 000720 ( PubMed/Checkpoint ); précédent : 000719; suivant : 000721Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Auteurs : Michael J. Overman [États-Unis] ; Ray Mcdermott [Irlande (pays)] ; Joseph L. Leach [États-Unis] ; Sara Lonardi [Italie] ; Heinz-Josef Lenz [États-Unis] ; Michael A. Morse [États-Unis] ; Jayesh Desai [Australie] ; Andrew Hill [Australie] ; Michael Axelson [États-Unis] ; Rebecca A. Moss [États-Unis] ; Monica V. Goldberg [États-Unis] ; Z Alexander Cao [États-Unis] ; Jean-Marie Ledeine [Belgique] ; Gregory A. Maglinte [États-Unis] ; Scott Kopetz [États-Unis] ; Thierry André [France]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux (usage thérapeutique), Antinéoplasiques (usage thérapeutique), Carcinomes (génétique), Carcinomes (secondaire), Carcinomes (traitement médicamenteux), Femelle, Humains, Instabilité des microsatellites, Mâle, Récepteur-1 de mort cellulaire programmée (antagonistes et inhibiteurs), Réparation de mésappariement de l'ADN, Résultat thérapeutique, Survie sans rechute, Tumeurs colorectales (anatomopathologie), Tumeurs colorectales (génétique), Tumeurs colorectales (mortalité).
- MESH :
- anatomopathologie : Tumeurs colorectales.
- antagonistes et inhibiteurs : Récepteur-1 de mort cellulaire programmée.
- génétique : Carcinomes, Tumeurs colorectales.
- mortalité : Tumeurs colorectales.
- secondaire : Carcinomes.
- traitement médicamenteux : Carcinomes.
- usage thérapeutique : Anticorps monoclonaux, Antinéoplasiques.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Instabilité des microsatellites, Mâle, Réparation de mésappariement de l'ADN, Résultat thérapeutique, Survie sans rechute.
English descriptors
- KwdEn :
- Adult, Antibodies, Monoclonal (therapeutic use), Antineoplastic Agents (therapeutic use), Carcinoma (drug therapy), Carcinoma (genetics), Carcinoma (secondary), Colorectal Neoplasms (genetics), Colorectal Neoplasms (mortality), Colorectal Neoplasms (pathology), DNA Mismatch Repair, Disease-Free Survival, Female, Humans, Male, Microsatellite Instability, Middle Aged, Programmed Cell Death 1 Receptor (antagonists & inhibitors), Treatment Outcome.
- MESH :
- chemical , antagonists & inhibitors : Programmed Cell Death 1 Receptor.
- chemical , therapeutic use : Antibodies, Monoclonal, Antineoplastic Agents.
- drug therapy : Carcinoma.
- genetics : Carcinoma, Colorectal Neoplasms.
- mortality : Colorectal Neoplasms.
- pathology : Colorectal Neoplasms.
- secondary : Carcinoma.
- Adult, DNA Mismatch Repair, Disease-Free Survival, Female, Humans, Male, Microsatellite Instability, Middle Aged, Treatment Outcome.
Abstract
Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.
DOI: 10.1016/S1470-2045(17)30422-9
PubMed: 28734759
Affiliations:
- Australie, Belgique, France, Irlande (pays), Italie, États-Unis
- Californie, Caroline du Nord, Minnesota, New Jersey, Texas, Île-de-France
- Paris
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28734759Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.</title><author><name sortKey="Overman, Michael J" sort="Overman, Michael J" uniqKey="Overman M" first="Michael J" last="Overman">Michael J. Overman</name><affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: moverman@mdanderson.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Mcdermott, Ray" sort="Mcdermott, Ray" uniqKey="Mcdermott R" first="Ray" last="Mcdermott">Ray Mcdermott</name><affiliation wicri:level="1"><nlm:affiliation>St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>St Vincent's University Hospital and Cancer Trials Ireland, Dublin</wicri:regionArea><wicri:noRegion>Dublin</wicri:noRegion></affiliation></author><author><name sortKey="Leach, Joseph L" sort="Leach, Joseph L" uniqKey="Leach J" first="Joseph L" last="Leach">Joseph L. Leach</name><affiliation wicri:level="2"><nlm:affiliation>Allina Health System, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Allina Health System, Minneapolis, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Lonardi, Sara" sort="Lonardi, Sara" uniqKey="Lonardi S" first="Sara" last="Lonardi">Sara Lonardi</name><affiliation wicri:level="1"><nlm:affiliation>Istituto Oncologico Veneto IOV-IRCSS, Padova, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Oncologico Veneto IOV-IRCSS, Padova</wicri:regionArea><wicri:noRegion>Padova</wicri:noRegion></affiliation></author><author><name sortKey="Lenz, Heinz Josef" sort="Lenz, Heinz Josef" uniqKey="Lenz H" first="Heinz-Josef" last="Lenz">Heinz-Josef Lenz</name><affiliation wicri:level="2"><nlm:affiliation>USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>USC Norris Comprehensive Cancer Center, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Morse, Michael A" sort="Morse, Michael A" uniqKey="Morse M" first="Michael A" last="Morse">Michael A. Morse</name><affiliation wicri:level="2"><nlm:affiliation>Duke University Medical Center, Durham, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Desai, Jayesh" sort="Desai, Jayesh" uniqKey="Desai J" first="Jayesh" last="Desai">Jayesh Desai</name><affiliation wicri:level="1"><nlm:affiliation>Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Victoria, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Victoria, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Hill, Andrew" sort="Hill, Andrew" uniqKey="Hill A" first="Andrew" last="Hill">Andrew Hill</name><affiliation wicri:level="1"><nlm:affiliation>Tasman Oncology Research Ltd, Southport, Queensland, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Tasman Oncology Research Ltd, Southport, Queensland, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Axelson, Michael" sort="Axelson, Michael" uniqKey="Axelson M" first="Michael" last="Axelson">Michael Axelson</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Moss, Rebecca A" sort="Moss, Rebecca A" uniqKey="Moss R" first="Rebecca A" last="Moss">Rebecca A. Moss</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Goldberg, Monica V" sort="Goldberg, Monica V" uniqKey="Goldberg M" first="Monica V" last="Goldberg">Monica V. Goldberg</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Cao, Z Alexander" sort="Cao, Z Alexander" uniqKey="Cao Z" first="Z Alexander" last="Cao">Z Alexander Cao</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ledeine, Jean Marie" sort="Ledeine, Jean Marie" uniqKey="Ledeine J" first="Jean-Marie" last="Ledeine">Jean-Marie Ledeine</name><affiliation wicri:level="1"><nlm:affiliation>Bristol-Myers Squibb, Braine-L'Alleud, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Bristol-Myers Squibb, Braine-L'Alleud</wicri:regionArea><wicri:noRegion>Braine-L'Alleud</wicri:noRegion></affiliation></author><author><name sortKey="Maglinte, Gregory A" sort="Maglinte, Gregory A" uniqKey="Maglinte G" first="Gregory A" last="Maglinte">Gregory A. Maglinte</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kopetz, Scott" sort="Kopetz, Scott" uniqKey="Kopetz S" first="Scott" last="Kopetz">Scott Kopetz</name><affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="André">Thierry André</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Universités, UMPC Paris 06, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Universités, UMPC Paris 06, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28734759</idno><idno type="pmid">28734759</idno><idno type="doi">10.1016/S1470-2045(17)30422-9</idno><idno type="wicri:Area/PubMed/Corpus">000531</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000531</idno><idno type="wicri:Area/PubMed/Curation">000529</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000529</idno><idno type="wicri:Area/PubMed/Checkpoint">000529</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000529</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.</title><author><name sortKey="Overman, Michael J" sort="Overman, Michael J" uniqKey="Overman M" first="Michael J" last="Overman">Michael J. Overman</name><affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: moverman@mdanderson.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Mcdermott, Ray" sort="Mcdermott, Ray" uniqKey="Mcdermott R" first="Ray" last="Mcdermott">Ray Mcdermott</name><affiliation wicri:level="1"><nlm:affiliation>St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>St Vincent's University Hospital and Cancer Trials Ireland, Dublin</wicri:regionArea><wicri:noRegion>Dublin</wicri:noRegion></affiliation></author><author><name sortKey="Leach, Joseph L" sort="Leach, Joseph L" uniqKey="Leach J" first="Joseph L" last="Leach">Joseph L. Leach</name><affiliation wicri:level="2"><nlm:affiliation>Allina Health System, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Allina Health System, Minneapolis, MN</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Lonardi, Sara" sort="Lonardi, Sara" uniqKey="Lonardi S" first="Sara" last="Lonardi">Sara Lonardi</name><affiliation wicri:level="1"><nlm:affiliation>Istituto Oncologico Veneto IOV-IRCSS, Padova, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Oncologico Veneto IOV-IRCSS, Padova</wicri:regionArea><wicri:noRegion>Padova</wicri:noRegion></affiliation></author><author><name sortKey="Lenz, Heinz Josef" sort="Lenz, Heinz Josef" uniqKey="Lenz H" first="Heinz-Josef" last="Lenz">Heinz-Josef Lenz</name><affiliation wicri:level="2"><nlm:affiliation>USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>USC Norris Comprehensive Cancer Center, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Morse, Michael A" sort="Morse, Michael A" uniqKey="Morse M" first="Michael A" last="Morse">Michael A. Morse</name><affiliation wicri:level="2"><nlm:affiliation>Duke University Medical Center, Durham, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Duke University Medical Center, Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Desai, Jayesh" sort="Desai, Jayesh" uniqKey="Desai J" first="Jayesh" last="Desai">Jayesh Desai</name><affiliation wicri:level="1"><nlm:affiliation>Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Victoria, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Victoria, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Hill, Andrew" sort="Hill, Andrew" uniqKey="Hill A" first="Andrew" last="Hill">Andrew Hill</name><affiliation wicri:level="1"><nlm:affiliation>Tasman Oncology Research Ltd, Southport, Queensland, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Tasman Oncology Research Ltd, Southport, Queensland, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Axelson, Michael" sort="Axelson, Michael" uniqKey="Axelson M" first="Michael" last="Axelson">Michael Axelson</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Moss, Rebecca A" sort="Moss, Rebecca A" uniqKey="Moss R" first="Rebecca A" last="Moss">Rebecca A. Moss</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Goldberg, Monica V" sort="Goldberg, Monica V" uniqKey="Goldberg M" first="Monica V" last="Goldberg">Monica V. Goldberg</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Cao, Z Alexander" sort="Cao, Z Alexander" uniqKey="Cao Z" first="Z Alexander" last="Cao">Z Alexander Cao</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ledeine, Jean Marie" sort="Ledeine, Jean Marie" uniqKey="Ledeine J" first="Jean-Marie" last="Ledeine">Jean-Marie Ledeine</name><affiliation wicri:level="1"><nlm:affiliation>Bristol-Myers Squibb, Braine-L'Alleud, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Bristol-Myers Squibb, Braine-L'Alleud</wicri:regionArea><wicri:noRegion>Braine-L'Alleud</wicri:noRegion></affiliation></author><author><name sortKey="Maglinte, Gregory A" sort="Maglinte, Gregory A" uniqKey="Maglinte G" first="Gregory A" last="Maglinte">Gregory A. Maglinte</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kopetz, Scott" sort="Kopetz, Scott" uniqKey="Kopetz S" first="Scott" last="Kopetz">Scott Kopetz</name><affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="André">Thierry André</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Universités, UMPC Paris 06, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Universités, UMPC Paris 06, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Carcinoma (drug therapy)</term><term>Carcinoma (genetics)</term><term>Carcinoma (secondary)</term><term>Colorectal Neoplasms (genetics)</term><term>Colorectal Neoplasms (mortality)</term><term>Colorectal Neoplasms (pathology)</term><term>DNA Mismatch Repair</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Male</term><term>Microsatellite Instability</term><term>Middle Aged</term><term>Programmed Cell Death 1 Receptor (antagonists & inhibitors)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Carcinomes (génétique)</term><term>Carcinomes (secondaire)</term><term>Carcinomes (traitement médicamenteux)</term><term>Femelle</term><term>Humains</term><term>Instabilité des microsatellites</term><term>Mâle</term><term>Récepteur-1 de mort cellulaire programmée (antagonistes et inhibiteurs)</term><term>Réparation de mésappariement de l'ADN</term><term>Résultat thérapeutique</term><term>Survie sans rechute</term><term>Tumeurs colorectales (anatomopathologie)</term><term>Tumeurs colorectales (génétique)</term><term>Tumeurs colorectales (mortalité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Programmed Cell Death 1 Receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs colorectales</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteur-1 de mort cellulaire programmée</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Carcinoma</term><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Carcinomes</term><term>Tumeurs colorectales</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs colorectales</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Carcinomes</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Carcinoma</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinomes</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>DNA Mismatch Repair</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Male</term><term>Microsatellite Instability</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Instabilité des microsatellites</term><term>Mâle</term><term>Réparation de mésappariement de l'ADN</term><term>Résultat thérapeutique</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28734759</PMID><DateCreated><Year>2017</Year><Month>07</Month><Day>23</Day></DateCreated><DateCompleted><Year>2017</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol.</ISOAbbreviation></Journal><ArticleTitle>Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.</ArticleTitle><Pagination><MedlinePgn>1182-1191</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(17)30422-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(17)30422-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6-18·0), 23 (31·1%, 95% CI 20·8-42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57-79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Bristol-Myers Squibb.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Overman</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: moverman@mdanderson.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Ray</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leach</LastName><ForeName>Joseph L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Allina Health System, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lonardi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Istituto Oncologico Veneto IOV-IRCSS, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenz</LastName><ForeName>Heinz-Josef</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morse</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Duke University Medical Center, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Jayesh</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Victoria, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tasman Oncology Research Ltd, Southport, Queensland, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Axelson</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Monica V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Z Alexander</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ledeine</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Braine-L'Alleud, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maglinte</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopetz</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>André</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Universités, UMPC Paris 06, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>31YO63LBSN</RegistryNumber><NameOfSubstance UI="C581771">nivolumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002277" MajorTopicYN="N">Carcinoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053843" MajorTopicYN="Y">DNA Mismatch Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053842" MajorTopicYN="Y">Microsatellite Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>05</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28734759</ArticleId><ArticleId IdType="pii">S1470-2045(17)30422-9</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(17)30422-9</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Belgique</li><li>France</li><li>Irlande (pays)</li><li>Italie</li><li>États-Unis</li></country><region><li>Californie</li><li>Caroline du Nord</li><li>Minnesota</li><li>New Jersey</li><li>Texas</li><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Overman, Michael J" sort="Overman, Michael J" uniqKey="Overman M" first="Michael J" last="Overman">Michael J. Overman</name></region><name sortKey="Axelson, Michael" sort="Axelson, Michael" uniqKey="Axelson M" first="Michael" last="Axelson">Michael Axelson</name><name sortKey="Cao, Z Alexander" sort="Cao, Z Alexander" uniqKey="Cao Z" first="Z Alexander" last="Cao">Z Alexander Cao</name><name sortKey="Goldberg, Monica V" sort="Goldberg, Monica V" uniqKey="Goldberg M" first="Monica V" last="Goldberg">Monica V. Goldberg</name><name sortKey="Kopetz, Scott" sort="Kopetz, Scott" uniqKey="Kopetz S" first="Scott" last="Kopetz">Scott Kopetz</name><name sortKey="Leach, Joseph L" sort="Leach, Joseph L" uniqKey="Leach J" first="Joseph L" last="Leach">Joseph L. Leach</name><name sortKey="Lenz, Heinz Josef" sort="Lenz, Heinz Josef" uniqKey="Lenz H" first="Heinz-Josef" last="Lenz">Heinz-Josef Lenz</name><name sortKey="Maglinte, Gregory A" sort="Maglinte, Gregory A" uniqKey="Maglinte G" first="Gregory A" last="Maglinte">Gregory A. Maglinte</name><name sortKey="Morse, Michael A" sort="Morse, Michael A" uniqKey="Morse M" first="Michael A" last="Morse">Michael A. Morse</name><name sortKey="Moss, Rebecca A" sort="Moss, Rebecca A" uniqKey="Moss R" first="Rebecca A" last="Moss">Rebecca A. Moss</name></country><country name="Irlande (pays)"><noRegion><name sortKey="Mcdermott, Ray" sort="Mcdermott, Ray" uniqKey="Mcdermott R" first="Ray" last="Mcdermott">Ray Mcdermott</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Lonardi, Sara" sort="Lonardi, Sara" uniqKey="Lonardi S" first="Sara" last="Lonardi">Sara Lonardi</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Desai, Jayesh" sort="Desai, Jayesh" uniqKey="Desai J" first="Jayesh" last="Desai">Jayesh Desai</name></noRegion><name sortKey="Hill, Andrew" sort="Hill, Andrew" uniqKey="Hill A" first="Andrew" last="Hill">Andrew Hill</name></country><country name="Belgique"><noRegion><name sortKey="Ledeine, Jean Marie" sort="Ledeine, Jean Marie" uniqKey="Ledeine J" first="Jean-Marie" last="Ledeine">Jean-Marie Ledeine</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="André">Thierry André</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000720 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000720 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28734759
|texte= Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28734759" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |